Dr. Steph Batalis and Vikram Venkatram offered the following comment in response to the National Institute of Standards and Technology's request for information on safety considerations for chemical and biological AI models.

Artificial intelligence (AI) tools pose exciting possibilities to advance scientific, biomedical, and public health research. At the same time, these tools have raised concerns about their potential to contribute to biological threats, like those from pathogens and toxins. This report describes pathways that result in biological harm, with or without AI, and a range of governance tools and mitigation measures to address them.

Medical artificial intelligence, which depends on large repositories of biological data, can improve public health and contribute to the growing global bioeconomy. Countries that strategically prioritize medical AI could benefit from a competitive advantage and set global norms. This report examines China’s stated goals for medical AI, finding that the country’s strategy for biodata collection and medical AI development positions it to be an economic and technological leader in this sector.

As the U.S. government considers banning genomics companies from China, it opens a broader question about how the United States and other market economies should deal with China’s “national champions.” This paper provides an overview of one such company—BGI—and how China’s industrial policy impacts technology development in China and around the world.

Recent government directives, international conferences, and media headlines reflect growing concern that artificial intelligence could exacerbate biological threats. When it comes to biorisk, AI tools are cited as enablers that lower information barriers, enhance novel biothreat design, or otherwise increase a malicious actor’s capabilities. In this explainer, CSET Biorisk Research Fellow Steph Batalis summarizes the state of the biorisk landscape with and without AI.

Antimicrobial resistance (AMR) is one of the world’s most pressing global health threats. Basic research is the first step towards identifying solutions. This brief examines the AMR research landscape since 2000, finding that the amount of research is increasing and that the U.S. is a leading publisher, but also that novel solutions like phages and synthetic antimicrobial production are a small portion of that research.

CSET submitted the following comment in response to a Request for Information (RFI) from the White House's Office of Science and Technology Policy about potential changes to the Policies for Federal and Institutional Oversight of Life Sciences Dual Use Research of Concern (DURC) and Recommended Policy Guidance for Departmental Development of Review Mechanisms for Potential Pandemic Pathogen Care and Oversight (P3CO).

Gain- and loss-of-function research have contributed to breakthroughs in vaccine development, genetic research, and gene therapy. At the same time, a subset of gain- and loss-of-function studies involve high-risk, highly virulent pathogens that could spread widely among humans if deliberately or unintentionally released. In this report, we map the gain- and loss-of-function global research landscape using a quantitative approach that combines machine learning with subject-matter expert review.

Vaccines keep the U.S. public healthy while safeguarding economic stability and biosecurity. This report assesses the domestic vaccine manufacturing landscape and identifies two major vulnerabilities: a reliance on foreign manufacturers and a lack of manufacturing redundancy. Maintaining a resilient vaccine supply will require the U.S. government to take steps to protect the existing supply, identify and monitor manufacturing vulnerabilities, and create a stronger domestic production base.

Pandemic threats are increasing as globalization, urbanization, and encroachment on animal habitats cause infectious outbreaks to become more frequent and severe. It is imperative that the United States build a pipeline of medical countermeasure development, beginning with basic scientific research and culminating in approved therapies. This report assesses preparedness for families of viral pathogens of pandemic potential and offers recommendations for steps the U.S. government can take to prepare for future pandemics.